Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Age As a Predictor of Tolerance with Ovarian Cancer

Gynecol Oncol; ePub 2017 Jan 10; Gillen, et al

Although older patients with ovarian cancer are less likely to enroll on clinical trial, women aged ≥70 years tolerated chemotherapy on trial as well as their younger counterparts, a recent study found. This retrospective cohort study included 336 patients (23.5% ≥70 years) with ovarian cancer enrolled in front line chemotherapy trials between 2000 and 2013. Patients were stratified by age: <70 and ≥70 years. Researchers found:

  • Patients ≥70 years completed a comparable number of chemotherapy cycles compared to those <70 years, with similar number of dose modifications and delays.
  • Both hematologic and non-hematologic toxicities occurred at similar rates.
  • Age ≥70 years (HR, 1.8), stage III/IV (HR, 3.44), and residual disease (HR, 2.63) were independently predictive of shorter overall survival.

Citation:

Gillen J, Gunderson C, Greenwade M, et al. Contribution of age to clinical trial enrollment and tolerance with ovarian cancer. [Published online ahead of print January 10, 2017]. Gynecol Oncol. doi:10.1016/j.ygyno.2016.12.023.